找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cancer Immunology; Bench to Bedside Imm Nima Rezaei Book 2021Latest edition Springer Nature Switzerland AG 2021 Cancer immunotherapy.Transl

[复制链接]
查看: 42380|回复: 68
发表于 2025-3-21 16:19:21 | 显示全部楼层 |阅读模式
书目名称Cancer Immunology
副标题Bench to Bedside Imm
编辑Nima Rezaei
视频video
概述Describes in detail novel strategies in cancer immunotherapy and targeting of tumor immunosuppression.Provides a bench to bedside approach to the immunology of cancers, with a focus on clinical aspect
图书封面Titlebook: Cancer Immunology; Bench to Bedside Imm Nima Rezaei Book 2021Latest edition Springer Nature Switzerland AG 2021 Cancer immunotherapy.Transl
描述.This translational, clinically oriented book describes in detail novel approaches to cancer immunotherapy, current strategies to target tumor immunosuppression, and prognostic biomarkers for personalized cancer treatments. Since the first, very successful edition of the book was published in 2015, the original chapters have been significantly updated and entirely new chapters are included on, for example, cancer immunoprevention, aptamer-mediated cancer gene therapy, haploidentical bone marrow transplantation for pediatric malignancies, and nanoimmunotherapy. .The book is published as part of the three-volume Springer series .Cancer Immunology., which aims to provide an up-to-date, clinically relevant review of cancer immunology and immunotherapy. Other volumes in the series address the translational medicine context and cancer immunotherapy for organ-specific tumors. .Cancer Immunology: Bench to Bedside Immunotherapy of Cancers. .will be of special value to clinical immunologists, hematologists, and oncologists... .
出版日期Book 2021Latest edition
关键词Cancer immunotherapy; Translational medicine; Prognostic biomarkers; Tumor immunosuppression; Gene thera
版次2
doihttps://doi.org/10.1007/978-3-030-50287-4
isbn_softcover978-3-030-50289-8
isbn_ebook978-3-030-50287-4
copyrightSpringer Nature Switzerland AG 2021
The information of publication is updating

书目名称Cancer Immunology影响因子(影响力)




书目名称Cancer Immunology影响因子(影响力)学科排名




书目名称Cancer Immunology网络公开度




书目名称Cancer Immunology网络公开度学科排名




书目名称Cancer Immunology被引频次




书目名称Cancer Immunology被引频次学科排名




书目名称Cancer Immunology年度引用




书目名称Cancer Immunology年度引用学科排名




书目名称Cancer Immunology读者反馈




书目名称Cancer Immunology读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

1票 100.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 20:34:36 | 显示全部楼层
Strategies to Target Tumor Immunosuppression,osuppression, are pivotal for potent antitumor immunity..This chapter provides an overview of the main immune tolerance and immunosuppression mechanisms within the tumor microenvironment and discusses effective immunotherapeutic interventions that target homing and activity of immune effector cells
发表于 2025-3-22 03:09:55 | 显示全部楼层
发表于 2025-3-22 07:29:43 | 显示全部楼层
发表于 2025-3-22 10:01:30 | 显示全部楼层
Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers,okines have demonstrated potential for therapeutic synergy. For example, it is possible to potentiate the development of specific immune response by reducing the dose of conventional chemotherapy (e.g., cyclophosphamide, gemcitabine, paclitaxel, and doxorubicin). This chapter provides currently evid
发表于 2025-3-22 14:33:42 | 显示全部楼层
发表于 2025-3-22 20:41:35 | 显示全部楼层
发表于 2025-3-22 23:33:33 | 显示全部楼层
Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T-Cells in Cancer Immunotoited to improve T-cell homing to tumors. The possibility of developing novel strategies to bring more T-cell effectors into tumors will surely enhance the efficacy of adoptive T-cell therapies. These strategies, also in combination with current checkpoint blockade, hold great promise for the future
发表于 2025-3-23 01:36:34 | 显示全部楼层
Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers,ancer progression. Hence, more investigations are required to discover proper therapeutic approaches for cancer. Multiple trials have been designed recently to detect the therapeutic role of TLR agonist in addition to chemotherapy. Also, the role of TLR agonist as a vaccine adjuvant for different ty
发表于 2025-3-23 08:59:14 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-29 03:14
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表